BAJAJ BROKING
Dr. Lal PathLabs reported a 9.8% revenue growth to ₹660 crore in Q2 FY24-25, while PAT increased by 18.1% to ₹130 crore. Growth was driven by core diagnostic services and wellness testing, reflecting the company’s market leadership and operational excellence.
Dr. Lal PathLabs Limited reported a consolidated revenue of ₹660 crore, showing a 9.8% increase year-on-year for Q2 FY24-25. The company also recorded a Profit After Tax (PAT) of ₹131 crore, reflecting an 18.1% YoY growth. The diagnostics giant continues to perform strongly despite evolving market conditions, maintaining its leadership in diagnostic services across India.
Dr. Lal PathLabs posted consolidated revenue of ₹660 crore in Q2 FY24-25, a 9.8% year-on-year increase compared to ₹601 crore in Q2 FY23-24. The company's Profit After Tax (PAT) for the quarter stood at ₹131 crore, marking an 18.1% growth compared to ₹111 crore in the same period last year. The robust performance is driven by continued demand for diagnostic services and the company’s expansion into new test categories.
Dr. Lal PathLabs’ Q2 results align with sector expectations, reflecting steady growth in the diagnostics market, driven by increasing demand for preventive healthcare services and routine testing. The sector continues to expand as awareness about health monitoring increases. The company's focus on wellness testing, along with a broad diagnostic portfolio, positions it strongly for future growth.
Dr. Lal PathLabs considered & took note that Dr. Om Prakash Manchanda will be stepping down as Managing Director of the Company on account of completion of tenure on March 31, 2025 (closing of business hours). However, after completion of tenure as Managing Director, he will remain as an advisor to the Company.
Particulars | Q2 FY24-25 (Reported) | YoY Change |
Revenue | ₹660.2 Cr | 9.80% |
EBITDA Margin | 30.70% | 13.90% |
PAT | ₹130.8 Cr | 18.10% |
Second Interim Dividend per Share | ₹ 6 |
|
Dr. Lal PathLabs’ Q2 FY24-25 results highlight its strong financial performance, with revenue growing by 9.8% and PAT increasing by 18.1%. The company’s ongoing focus on expanding its diagnostic portfolio and preventive health offerings continues to fuel growth, positioning it as a leader in the diagnostics industry.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading